IL164783A - Use of epothilone derivatives for the preparation of medicaments for treating cancer diseases - Google Patents

Use of epothilone derivatives for the preparation of medicaments for treating cancer diseases

Info

Publication number
IL164783A
IL164783A IL164783A IL16478304A IL164783A IL 164783 A IL164783 A IL 164783A IL 164783 A IL164783 A IL 164783A IL 16478304 A IL16478304 A IL 16478304A IL 164783 A IL164783 A IL 164783A
Authority
IL
Israel
Prior art keywords
treatment
cancer
progressing
radiotherapy
use according
Prior art date
Application number
IL164783A
Other languages
English (en)
Other versions
IL164783A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL164783A0 publication Critical patent/IL164783A0/xx
Publication of IL164783A publication Critical patent/IL164783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL164783A 2002-05-01 2004-10-21 Use of epothilone derivatives for the preparation of medicaments for treating cancer diseases IL164783A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (2)

Publication Number Publication Date
IL164783A0 IL164783A0 (en) 2005-12-18
IL164783A true IL164783A (en) 2011-08-31

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL164783A IL164783A (en) 2002-05-01 2004-10-21 Use of epothilone derivatives for the preparation of medicaments for treating cancer diseases

Country Status (23)

Country Link
US (2) US20050282873A1 (enExample)
EP (1) EP1503756B1 (enExample)
JP (1) JP2005528414A (enExample)
KR (1) KR20040106422A (enExample)
CN (1) CN1649585A (enExample)
AT (1) ATE439130T1 (enExample)
AU (1) AU2003227702B2 (enExample)
BR (1) BR0309711A (enExample)
CA (1) CA2483826C (enExample)
CY (1) CY1109607T1 (enExample)
DE (1) DE60328772D1 (enExample)
DK (1) DK1503756T3 (enExample)
ES (1) ES2330324T3 (enExample)
IL (1) IL164783A (enExample)
MX (1) MXPA04010853A (enExample)
NO (1) NO20045249L (enExample)
NZ (1) NZ536178A (enExample)
PL (1) PL211114B1 (enExample)
PT (1) PT1503756E (enExample)
RU (1) RU2358730C2 (enExample)
SI (1) SI1503756T1 (enExample)
WO (1) WO2003092683A1 (enExample)
ZA (1) ZA200408492B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний
BRPI0414043A (pt) * 2003-09-02 2006-10-24 Novartis Ag tratamento de cáncer com epotilonas
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
ATE254615T1 (de) * 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний

Also Published As

Publication number Publication date
IL164783A0 (en) 2005-12-18
CN1649585A (zh) 2005-08-03
RU2358730C2 (ru) 2009-06-20
PL211114B1 (pl) 2012-04-30
AU2003227702B2 (en) 2007-07-26
ES2330324T3 (es) 2009-12-09
CA2483826C (en) 2012-04-17
MXPA04010853A (es) 2005-02-14
US20080161369A1 (en) 2008-07-03
RU2004135307A (ru) 2005-09-10
NZ536178A (en) 2007-10-26
EP1503756B1 (en) 2009-08-12
PL371727A1 (en) 2005-06-27
DK1503756T3 (da) 2009-11-16
WO2003092683A1 (en) 2003-11-13
NO20045249L (no) 2005-01-26
AU2003227702A1 (en) 2003-11-17
HK1073601A1 (en) 2005-10-14
SI1503756T1 (sl) 2010-01-29
DE60328772D1 (de) 2009-09-24
CA2483826A1 (en) 2003-11-13
ZA200408492B (en) 2006-09-27
JP2005528414A (ja) 2005-09-22
US20050282873A1 (en) 2005-12-22
CY1109607T1 (el) 2014-08-13
ATE439130T1 (de) 2009-08-15
PT1503756E (pt) 2009-10-28
BR0309711A (pt) 2005-02-09
EP1503756A1 (en) 2005-02-09
KR20040106422A (ko) 2004-12-17

Similar Documents

Publication Publication Date Title
US20080161369A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
US7091226B2 (en) Cancer treatment with epothilones
US6302838B1 (en) Cancer treatment with epothilones
JP2002504511A5 (enExample)
EP1104297B1 (en) Compositions for the treatment of chronic lymphocytic leukemia
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
BG108112A (bg) Методи за въвеждане на аналози на епотилон за лечение на карциноми
JP2005527576A (ja) エポチロン化合物の経口投与
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
KR20240158972A (ko) 소세포 폐암의 치료 방법
CN101357134A (zh) 抗肿瘤效果增强剂和抗肿瘤剂
JP2005503323A5 (enExample)
KR20010072228A (ko) 위장 독성이 감소된 캠프토테신 유도체의 용도
HK1073601B (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
US20110152329A1 (en) Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism
RU2242229C2 (ru) Применение эпотилонов для лечения рака
CN112439061A (zh) 法米替尼或其可药用盐联合pd-1抗体的新用途
HK1255299B (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers
HK1255299A1 (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers
HK1080768B (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
HK1104780A (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees